Meta analysis on efficacy and safety of transcatheter arterial chemoembolization combined with S-1 for primary hepatic carcinoma
SUI Jing
MAN Mu-ran
ZHOU Xu-lin
GONG Ping
LIU Qing-hua
Abstract：Objective To assess the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with S-1 in the treatment of primary hepatic carcinoma (PHC). Methods The published clinical studies regarding the comparison of TACE combined with S-1 and TACE alone in treatment of PHC were collected through a computer-based retrieval from the launching to February 2018, by using PubMed, Embase, Cochrane and China National Knowledge Internet Full-text Databases. RevMan 5.3 software was used for Meta analysis. Publication bias was assessed with Begg and Egger. Results Nine studies involving in 569 PHC cases were enrolled in this study, including 8 randomized controlled trials and 1 cohort study. The objective response rate and disease control rate of TACE combined with S-1 in treatment of PHC were 69.8% and 89.9% respectively, which were higher than those of TACE alone, 42.9% and 65.6% (P＜0.05). The one-year, two-year and three-year overall survival rates of TACE combined with S-1 in treatment of PHC were 80.00%, 49.74% and 37.64%, which were obviously higher than those of TACE alone (53.33%, 24.10% and 14.12%, P ＜ 0.05). Adverse events were mainly bone marrow suppression, nausea, vomiting, abdominal pain and fever, which were improved after symptomatic treatment. No other severe adverse events were observed. Conclusions S-1 combined with TACE in the treatment of PHC is superior to TACE alone. It can improve clinical effect and overall survival rate with tolerable adverse reactions.
Keywords：primary hepatic carcinomaTACES-1combined treatmentMeta analysis
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 220-226 )